LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 601cells, culture experiments with, 1, 8
of cervix
causes of, 315, 323
5FU with cisplatin, 317, 325
HIV and, 316
HPV and, 39, 51, 143, 315,
323, 324
HPV-16 and, 39, 51
and HPV vaccine, 106, 111
lymph-vascular space invasion
in, 316
microinvasive carcinoma and,
324
MRI in, 168, 181
myometrial invasion of, 168,
181
nodal involvement, 316, 324
pathogenesis of, 39, 51
PET scanning of, 317, 325
radiation therapy, 317, 325
smoking and, 39, 51
staging of, 317, 324–325
surgery in, 317, 325
tumor size, 316, 324
in United States, 315, 323
of colon, 23, 31
CDX2 and, 161, 170
COX-2 inhibitor and, 42, 54
KRAS mutation testing in, 123,
129
Lynch syndrome and, 45, 153,
159
microsatellite instability in, 4,
11
MMR protein expression in,
123
relapses in early-stage, 97, 101
risk and obesity, 62, 68
treatment, oxaliplatin with 5FU
for, 270, 275
UGT1A1∗28 testing in, 123
colorectal
alcohol consumption and, 61, 67
bevacizumab, 273, 277
cetuximab, 98, 103
colonoscopy for, 269, 274–275
CT colography of, 168, 180
FAP and, 137, 140
fecal occult blood testing in,
142, 146
FOLFOX and FOLFIRI in, 273,
277
K-RAS mutation and, 272, 277
MRI of, 168, 180
MSI and, 269, 272, 274, 277
NSAID in, 136, 139
panitumumab, 273, 277
red meat consumption and, 62,
67treatment, cetuximab in, 97,
102
TRUS of, 168, 180
development of, 57, 63
diet and, 61, 66
DNA double-strand break
induction and, 60, 66
EBV and, 40, 52
endometrial
-catenin mutation in, 315, 323
BCL2 overexpression in, 315,
323
chemotherapy in, 321, 328, 329
diabetes mellitus and, 320, 327
estrogen therapy and, 327
HER2/neu amplification in,
315, 323
hysterectomy and, 320, 327
KRAS mutation in, 315, 323
Lynch syndrome and, 153, 159
obesity and, 62, 68, 320, 327
p53 mutations in, 315, 323
PTEN mutation in, 315, 323
radiation therapy in, 321,
327–328
recurrence of, 321, 328–329
risk factors for, 315, 320, 323,
327
serum CA-125 and, 321, 329
staging system of, 320, 328
treatment, cis-
platin/doxorubicin/paclitaxel
in, 321, 329
type I characteristics, 314, 323
type II characteristics, 314, 323
of esophagus, 231, 238
achalasia and, 231, 238
and Barrett’s esophagus, 142,
145
capecitabine and, 234, 240
chemoradiotherapy in, 235,
240–241
E-cadherin expression in, 237
EGFR overexpression in, 237
FDG-PET in, 233, 240
gastroesophageal reflux disease
and, 142, 145
incidence rates of, 231
andN-nitrosamines, 43
oxaliplatin and, 234, 240
Plummer–Vinson syndrome
and, 231, 238
p53 point mutation in, 237
preoperative radiotherapy and
chemoradiotherapy, 233,
239–240
risk factors of, 231, 238
and smokeless tobacco, 34, 44
tylosis and, 231, 238gastric
adjuvant radiation therapy of,
236, 241–242
chemotherapy in, 236, 242
EBV and, 52
E-cadherin and, 232, 233,
238–239, 239
microsatellite instability in, 233,
237, 239, 243
mitomycin C in, 242
prophylactic gastrectomy in,
237, 243
p53 tumor suppressor gene and,
233, 239
gene amplification in, 4, 11
genetic mutations in, 1
gain-of-function mutations, 1
loss-of-functions mutations, 1
growth, tyrosine kinases for,
14–15
her2/neu amplification in, 4, 11
HIV infection and, 38, 49
infectious agent in, 41, 54
and inflammation association, 41,
53–54
initiation and genetic changes, 34,
44
Knudson’s hypothesis and, 34, 44
linear model and, 59, 65
of liver
aflatoxins exposure and, 57, 63
staging systems, 253, 257
of lung
asbestos and, 60, 66
CHRNA3 gene and, 72, 76
cigarette smoking and, 33, 43,
70, 74
CT for, 71, 75
in developing countries, 72, 76
EGFR and, 205, 210
environmental factors and, 72,
76
KRAS oncogene in, 44
molecular abnormalities in,
205, 210
mortality by, 76
MRI of, 166, 178
N-nitrosamines and, 43
percutaneous thermal ablation
of, 162, 170
polycyclic aromatic
hydrocarbons and, 33, 43
screening of, 166, 178
smoking and, 72, 76
staging, PET/CT in, 166, 178
and tobacco, 57, 63
treatment planning, 167,
178–179
mortality, obesity and, 61, 67